Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

Next Previous
X
Search
Trial Profile

CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Bicalutamide; Flutamide; Luteinising hormone stimulants; Luteinising hormone stimulants
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms CHAARTED

    • Most Recent Events

    • 04 Jun 2024 Results (n=68) assessing Whole exome correlates in metastatic hormone sensitive prostate cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 14 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Jul 2024.
    • 24 Oct 2023 Results comparing treatment regimens androgen deprivation therapy or docetaxel in the control or research arms in mHSPC were utilized from 13 trials which includes (NCT00002651, NCT00216060, NCT00079001, NCT00104715, NCT00268476, NCT00309985, NCT00685646) studies, presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top